Biogen (BIIB) Cash & Equivalents (2009 - 2026)
Biogen (BIIB) reported Cash & Equivalents of $1.3 billion for Q3 2026, down 66.2% from $3.86 billion a year earlier but up 1.5% from the prior quarter.
Powered by 
Analysis
Biogen (BIIB) Cash & Equivalents (2009 - 2026) Analysis & Trends
At the end of FY2025, Biogen posted Cash & Equivalents of $3.01 billion, up 26.7% from FY2024.
- Cash & Equivalents has a five-year compound annual growth rate of 17.7% (FY2020 to FY2025).
- By year, Cash & Equivalents came in at $2.38 billion in FY2024 (+126.2%), $1.05 billion in FY2023 (-69.3%), $3.42 billion in FY2022 (+51.2%) and $2.26 billion in FY2021 (+69.9%).
- Five-year quarterly Cash & Equivalents spans a low of $1.05 billion in Q4 2023 and a high of $3.86 billion in Q3 2025.
- Year over year, Cash & Equivalents gained in six of the last eight quarters, with growth averaging 47.1%.
- The high point for year-over-year Cash & Equivalents in five years was Q1 2025 (growth of 141.8%); the low point was Q4 2023 (a decline of 69.3%).
- Per Business Quant data, the three quarters before Q3 2026 came in at $1.29 billion (Q2 2026), $3.38 billion (Q1 2026) and $3.01 billion (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,359.75 Bn | 1,333.37 Bn | 20.46 Bn | 4.89 Bn |
| 2 | Johnson & Johnson | 688.76 Bn | 608.62 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 521.69 Bn | 489.75 Bn | 13.12 Bn | 10.77 Bn |
| 4 | Merck | 364.31 Bn | 327.31 Bn | 13.19 Bn | 9.55 Bn |
| 5 | Novartis Ag | 306.35 Bn | 279.93 Bn | - | 400.00 Mn |
| 6 | Astrazeneca | 285.96 Bn | 259.56 Bn | 13.26 Bn | 7.94 Bn |
| 7 | Amgen | 251.88 Bn | 203.53 Bn | 7.58 Bn | 13.19 Bn |
| 8 | Gilead Sciences | 208.59 Bn | 183.61 Bn | 6.73 Bn | 6.44 Bn |
| 9 | Pfizer | 164.73 Bn | 112.38 Bn | 12.56 Bn | 1.82 Bn |
| 10 | Biogen | 37.46 Bn | 26.77 Bn | 2.06 Bn | 1.30 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 1.30 Bn |
| Jun 30, 2026 | 1.29 Bn |
| Mar 31, 2026 | 3.38 Bn |
| Dec 31, 2025 | 3.01 Bn |
| Sep 30, 2025 | 3.86 Bn |
| Jun 30, 2025 | 2.76 Bn |
| Mar 31, 2025 | 2.60 Bn |
| Dec 31, 2024 | 2.38 Bn |
| Sep 30, 2024 | 1.70 Bn |
| Jun 30, 2024 | 1.91 Bn |
| Mar 31, 2024 | 1.07 Bn |
| Dec 31, 2023 | 1.05 Bn |
| Sep 30, 2023 | 2.29 Bn |
| Jun 30, 2023 | 2.62 Bn |
| Mar 31, 2023 | 2.90 Bn |
| Dec 31, 2022 | 3.42 Bn |
| Sep 30, 2022 | 3.68 Bn |
| Jun 30, 2022 | 2.65 Bn |
| Mar 31, 2022 | 1.75 Bn |
| Dec 31, 2021 | 2.26 Bn |
API Access
Biogen Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=BIIB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "BIIB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=BIIB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();